New Fairfield, CT, United States of America

John J Freeman

This inventor holds 34 USPTO granted patents and 29 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Diketopiperazine Synthesis. Top assignees: Mannkind Corporation, Bsh Home Appliances Corporation, Emisphere Technologies, Inc.. Active years: 1988-2025.

USPTO Granted Patents = 34 (Patent Applications = 29)

% Patents Active = 94.1

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 167(Granted Patents)

Location History:

Westchester, NY (US) (1992)
Webster Groves, MO (US) (1988 - 1994)
Valhalla, NY (US) (1999)
Fairfield, CT (US) (2004)
Knoxville, TN (US) (2015 - 2018)
New Fairfield, CT (US) (2006 - 2024)

Company Filing History:

Bsh Home Appliances Corporation

patents

5 out of 183

Emisphere Technologies, Inc.

patents

4. 1 out of 3,580

American Cyanamid Company

7. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2025

Loading Chart...

Areas of Expertise:

Diketopiperazine

Activated Ethylfumarates

Microparticles

Cooking Appliance

Home Appliance

Self-Filling Cup

Electrode Chamber

Phenoxy Carboxylic Acid

Chemiluminescent Device

Salicyloylamino Acids

Phosphorus Trichloride

Gas Production

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459903 - Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2025-11-04),

2. 12383552 - Diketopiperazine microparticles with defined specific surface areas (2025-08-12),

3. 12202807 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2025-01-21),

4. 12049453 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester (2024-07-30),

5. 11607410 - Diketopiperazine microparticles with defined specific surface areas (2023-03-21),

6. 11479535 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2022-10-25),

7. 11440891 - Formation of N-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2022-09-13),

8. 11345668 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester (2022-05-31),

9. 10870628 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester (2020-12-22),

10. 10858325 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2020-12-08),

11. 10772883 - Diketopiperazine microparticles with defined specific surface areas (2020-09-15),

12. 10640471 - Formation of N-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2020-05-05),

13. 10577331 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester intermediate (2020-03-03),

14. 10196366 - Formation of N-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2019-02-05),

15. 10143327 - Cooktop steamer with self-filling cup (2018-12-04),

Sure, I can help you with that. Here is the article on inventor John J Freeman:

Title: Inventor Spotlight: John J Freeman - Pioneering Innovations in Chemistry

Introduction:

John J Freeman, a distinguished inventor in the field of chemistry, hails from New Fairfield, CT, in the United States. With an impressive portfolio of 30 patents to his name, Freeman has made significant contributions to the realm of pharmaceuticals and chemical synthesis.

Latest Patents:

Among his latest patented inventions are groundbreaking developments in pharmaceutical microparticles. One of his patents focuses on diketopiperazine microparticles with defined specific surface areas, particularly suited for drug delivery systems such as insulin. Another notable patent discloses innovative methods for the synthesis of activated fumarate esters, enhancing chemical synthesis processes.

Career Highlights:

Freeman has garnered experience and expertise through his tenure at reputable companies such as Mannkind Corporation and Emisphere Technologies, Inc. His dedication to innovation and his adept skills have driven advancements in drug delivery technologies, solidifying his status as a trailblazer in the field.

Collaborations:

Throughout his career, John J Freeman has collaborated with esteemed professionals in the industry, including Kelly Sullivan Kraft and Otto Phanstiel. These collaborations have led to synergistic efforts in research and development, resulting in the successful implementation of novel technologies and methodologies.

Conclusion:

In conclusion, John J Freeman stands as a visionary inventor whose relentless pursuit of excellence has reshaped the landscape of pharmaceutical innovation. With a strong foundation in chemistry and a passion for pioneering solutions, Freeman continues to push boundaries and strive for excellence in his field.